Revolution Medicines counsel sells 2,958 shares

Revolution Medicines General Counsel Jeff Cislini reported selling 2,958 shares of common stock in two open-market transactions.

Rhea-AI Filing Summary

Revolution Medicines General Counsel Jeff Cislini reported selling 2,958 shares of common stock in two open-market transactions. On March 17, he sold 1,795 shares at $99.4804 per share, and on March 19 he sold 1,163 shares at $97.44 per share. One sale was made under a Rule 10b5-1 instruction letter related to tax withholding on vested RSUs, and the other under a 10b5-1 trading plan. After these sales, he directly holds 58,518 shares, including 48,125 RSUs.

Insider Trade Summary 10b5-1

Net Seller: 2,958 shares

Net Sell 2 txns

Insider Cislini Jeff

Role General Counsel

Sold 2,958 shs ($292K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,163	$97.44	$113K
Sale	Common Stock	1,795	$99.4804	$179K

Holdings After Transaction: Common Stock — 58,518 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. F2. Includes 48,125 RSUs.
3. F3. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Revolution Medicines (RVMD) report for Jeff Cislini?

Revolution Medicines reported that General Counsel Jeff Cislini sold 2,958 shares of common stock in two open-market transactions. These occurred on March 17 and March 19, 2026, at prices near $99.48 and $97.44 per share, respectively.

Were the recent RVMD insider stock sales by Jeff Cislini pre-planned?

Yes. One transaction was executed under a Rule 10b5-1 instruction letter adopted on May 31, 2023 for RSU tax withholding, and the other followed a 10b5-1 trading plan adopted on March 13, 2025, indicating pre-scheduled activity.

How many Revolution Medicines (RVMD) shares did Jeff Cislini sell and at what prices?

Jeff Cislini sold a total of 2,958 RVMD shares. He sold 1,795 shares at $99.4804 per share on March 17, 2026, and 1,163 shares at $97.44 per share on March 19, 2026, in open-market sales.

How many Revolution Medicines (RVMD) shares does Jeff Cislini hold after these sales?

Following the transactions, Jeff Cislini directly holds 58,518 shares of Revolution Medicines common stock. This figure includes 48,125 restricted stock units (RSUs), which represent shares that will be delivered as they vest under existing equity awards.

What is the role of restricted stock units (RSUs) in Jeff Cislini’s RVMD ownership?

Jeff Cislini’s reported holdings include 48,125 RSUs, which are rights to receive RVMD shares as vesting conditions are met. One of the disclosed transactions relates to a Rule 10b5-1 instruction letter used to cover tax withholding on vesting RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 06:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		1,795	D	$99.4804	59,681(2)	D
Common Stock	03/19/2026		S(3)		1,163	D	$97.44	58,518(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 48,125 RSUs.

3. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)